Pfizer CEO rules out talk with China on generic Covid drug Paxlovid license

Bourla said the company had shipped thousands of courses of the treatment in 2022 to China and in the past couple of weeks, had increased that to millions

Pfizer Inc is not in talks with Chinese authorities to license a generic version of its COVID-19 treatment Paxlovid for use there, but is in discussions about a price for the branded product, Chief Executive Albert Bourla said on Monday.

Reuters reported on Friday that China was in talks with Pfizer to secure a license that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm's COVID-19 antiviral drug Paxlovid in China.
 

Referring to that report, Bourla speaking at J.P. Morgan's healthcare conference in San Francisco, said "We are not in discussions. We have an